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Infection by protozoan parasites is part of the most common Tropical Neglected Diseases.
In the case of leishmaniasis, several millions of people are at risk of contracting the dis-
ease. In spite of innumerous studies that elucidated the immune response capable of
killing the parasite, the understanding of the evasion mechanisms utilized by the parasite
to survive within the very cell responsible for its destruction is still incomplete. In this
review, we offer a new approach to the control of the immune response against the
parasite. The ability of the parasite to modulate the levels of extracellular ATP and aden-
osine either by directly acting on the levels of these molecules or by inducing the
expression of CD39 and CD73 on the infected cell may influence the magnitude of the
immune response against the parasite contributing to its growth and survival.Leishmaniasis comprises a group of parasitic diseases caused
by several species of the Leishmania genus. Depending on the
combination of the parasite species and yet unknown factors
of the host, the disease can manifest itself as a single cuta-
neous ulcer, multiple lesions throughout the body or even
visceral infection which, when untreated, is often lethal [1].
The disease is transmitted by infected females of sand flies of
the Phlebotominae family during blood feeding [2] and affectsy Laboratory, Departmen
Brazil. Tel.: þ55 31 35591
.C.C. Afonso).
g Gung University.
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/by-nc-nd/4.0/).approximately 300,000 people worldwide annually, mainly in
the tropical and subtropical areas [3].
The immune response against the parasite is dependent
both on the innate as well as the adaptative responses (for
recent reviews, see [4e7]). In this review we will focus pri-
marily on the innate aspects of the immune response and the
role of the purinergic signaling in the modulation of such
response.t of Biological Sciences, ICEB/NUPEB, Federal University of Ouro
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During blood feeding of infected phlebotomine females, neu-
trophils rapidly migrate to the site of infection and phagocy-
tize metacyclic promastigotes that are injected together with
the insect saliva [8,9]. The role of neutrophils during infection
is contradictory. These cells have been reported to help
eliminate the parasite via the production of ROS and the in-
duction of extracellular traps [10,11]. However, they also may
play a role in inhibiting macrophage activation, due to their
death by apoptosis after infection by the parasite [12]. Neu-
trophils also secrete chemokines that recruit monocytes/
macrophages as well as dendritic cells to the site of infection
[4,13].
Dendritic cells (DC) are antigen presenting cells capable
of producing IL-12 upon infection with some Leishmania
species such as Leishmania major [14]. This production of IL-
12 is crucial to the development of a specific Th1 response
that is protective to the host [15,16]. However, Leishmania
amazonensis, which causes a severe form of cutaneous
leishmaniasis (diffuse cutaneous leishmaniasis) character-
ized by the lack of specific immune response in patients [17],
inhibits DC activation and interfere with antigen presenta-
tion and development of T cell response [18] thus evading
the immune response both in humans and in the mouse
model [17e21].
Even though Leishmania can infect neutrophils and DC,
macrophages are the cells in which these parasites live and
multiplywithin the infectedmammalian host. Leishmania gain
access to macrophages via phagocytosis mediated by com-
plement fragments that are deposited and inactivated on the
surface of the parasite, due to the action of proteases present
on the surface of the infective promastigote [22e25]. The entry
of the parasite via complement receptor (CR3)-mediated
phagocytosis interferes with macrophage activation allowing
the parasite to prevent the initial respiratory burst that,
otherwise, would destroy the parasite [26]. However, upon
activation by IFN-g [27,28], produced by both NK [29] and T
cells (both CD4 [30] and CD8 [31]), macrophages are activated
to produce ROS and NO which are the main effector mecha-
nisms for parasite killing within these cells [32].
In spite of the potential ability of the host to control para-
site growth, several mechanisms contribute to evasion of the
immune response by Leishmania. These mechanisms include,
in addition to those already mentioned above, escape from
complement activation [26,33], inhibition of macrophage
activation by apoptotic neutrophil [12], production of inhibi-
tory cytokines such as IL-10 and TGF-b by macrophages and
DC, and the induction of regulatory T cells capable of con-
trolling the immune response [4,19,21]. Although these
inhibitory mechanisms have been extensively studied, the
evasion of the immune response by some parasite species, in
special L. amazonensis, is not restricted to these mechanisms.
For example, IL-10 deficient mice infected with L. amazonensis
still develop lesions in spite of an increased Th1 response [34].
Thus, it is conceivable that other mechanisms of immune
evasion are present during Leishmania infection and modula-
tion of the immune response via purinergic signaling may be
one of such mechanisms.Purinergic signaling and inflammation
During infection or cell injury, ATP can be released to the
extracellularmilieu and has been described as a danger signal,
alerting the immune system to alterations in cellular integrity
[35e38]. ATP can also be released by intact cells through
conexin and panexin channels and also via the P2X7 receptor
[39].
Extracellular ATP is a potent inducer of inflammation
characterized by macrophage and DC activation and
increased production of IL-12 and TNF-a by these cells [40e45].
ATP exerts its effects by binding to P2 receptors which are
divided in two subtypes: P2X receptors, that are associated to
ionic channels and protein G coupled-P2Y [46e48]. In immune
cells, P2X7 is the main ATP receptor and its activation ac-
counts for most of the inflammatory effects of extracellular
ATP [49e51].
In order to regulate the extracellular effects of ATP, its
concentration is controlled by the action of extracellular en-
zymes ofwhich themain players in immune cells are the ecto-
NTPDase (CD39) that hydrolyses ATP to ADP and subsequently
to AMP and the ecto-50-nucleotidase (CD73) that removes the
phosphate group of AMP leading to the production of adeno-
sine. Adenosine is, then, deaminated to inosine by adenosine
deaminase [52,53]. In addition, adenosine concentrations in-
side and outside the cell are kept relatively constant (between
30 and 300 nM) by the action of bidirectional nucleoside
transporters. However, in pathophysiological conditions such
as hypoxia, ischemia and cell injury, adenosine extracellular
concentrations can peak at 10 mM [54e56].
By acting on P1 receptors, in particular A2A and A2B, aden-
osine counteracts the inflammatory effects of ATP [57]. Thus
adenosine inhibits the production of inflammatory cytokines
by macrophages and DC and the production of microbicidal
effectors by neutrophils and macrophages. In addition,
adenosine stimulates the synthesis of IL-10, one of the major
regulatory cytokines [47,58e63].
Thus, the balance between extracellular ATP and adeno-
sine can contribute to the control of inflammation by,
respectively, stimulating or inhibiting the cells involved in the
immune response. Next, we present data from the recent
literature that show that the purinergic system may interfere
with the establishment of infection by Leishmania.The role of saliva
As mentioned above, Leishmania promastigotes are trans-
mitted by the bite of an infected phlebotomine. During blood
feeding, the insect regurgitates and a portion of saliva is
inoculated in the host dermis. In order to facilitate the blood
meal, phlebotomine saliva is endowed with several sub-
stances that prevent blood clotting formation. Thus, saliva
from phlebotomine sand flies (Phlebotomus papatasi and Phle-
botomus argentipes) is rich in adenosine and AMP [64e66]. In
addition, transcriptome analysis indicated the presence of
apyrases and 50-nucleotidases in the saliva of Lutzomyia long-
ipalpis [67], Phlebotomus perniciosus, P. argentipes, Phlebotomus
ariasi [68] and Phlebotomus duboscqi [69]. AMP and adenosine
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ases in the saliva contributes to the hydrolysis of extracellular
ATP, preventing platelet aggregation and blood clot formation
[71].
In addition to prevention of blood clotting, the presence of
adenosine, AMP and ectonucleotidasesmay also influence the
host immune response and facilitate the establishment of the
infection. It has been demonstrated that addition of salivary
gland extract together with the parasite exacerbates lesion
development in the murine model of leishmaniasis [72e75].
Recent studies by Carregaro and colleagues [76] demonstrated
that adenosine and AMP present in the saliva of P. papatasi
exacerbate lesion development in L. amazonensis infected
mice, probably due to increased IL-10 production and induc-
tion of tolerogenic dendritic cells and regulatory T cells. These
effects seem to be mediated by the A2A adenosine receptor.
Corroborating the role of nucleotides and nucleosides of the
insect saliva in the immunomodulation of the host response
Katz and colleagues [64] demonstrated that P. papatasi saliva
decreases NO production by activated macrophages. The
same was not observed when the saliva of L. longipalpis is
used. Interestingly, the levels of AMP are smaller in the saliva
of L. longipalpis than in the saliva of P. papatasi. In addition,
adenosine deaminase activity has been observed in the saliva
of L. longipalpis [77] and P. duboscqi [78], but not in the saliva of
P. papatasi [78]. The presence of adenosine deaminase could
contribute to a decrease in adenosine concentration at the bite
site thus inhibiting the modulatory effect of the saliva.
Altogether, these results indicate a strong involvement of
the purinergic signaling pathway during the first moments of
the inoculation of the parasite in the host dermis.Leishmania ectonucleotidases
In addition to the effects promoted by the insect saliva, ecto-
enzymes present on the surface of the promastigote may
also contribute to the establishment of the infection by
Leishmania.
Leishmania and other trypanosomatids are incapable of de
novo synthesis of the purine ring and thus depend on salvage
pathways to synthetize purine nucleotides [79,80]. In order to
obtain nucleosides from the external medium these parasites
express ectonucleotidases thus enabling the external hydro-
lysis of nucleotides to the respective nucleosides.
Amongst the several ectonucleotidases the ecto-
nucleoside triphosphate diphosphohydrolase (E-NTPDase e
EC 3.6.1.5) and the ecto-50-nucleotidase (EC 3.1.3.5) have been
shown to exert important roles in the infection by Leishmania.
E-NTPDase has been reported on Leishmania tropica [81] and L.
amazonensis [82,83]. In addition to E-NTPDase, we also
demonstrated that L. amazonensis presents ecto-50-nucleo-
tidase activity [84].
Several studies have associated the presence of E-NTPDase
and ecto-50-nucleotidase activities to the virulence of different
Leishmania species [82,84e86]. Thus, parasites with increased
ectonucleotidase activity are more capable of infecting mac-
rophages [87] and induce larger lesions in mice [84,86].
Furthermore, we have demonstrated a positive correlation
between the ATP, ADP and AMP hydrolytic activity inLeishmania braziliensis isolates and their ability to control the
establishment of the immune response in mice. More impor-
tantly, a positive correlation between the nucleotide hydro-
lytic activity and the severity of the clinical manifestation was
also observed [85]. Similarly, L. amazonensis isolates with
different ectonucleotidase activity show distinct capacity to
survive in infectedmacrophages and to down-modulate nitric
oxide production [87]. Interestingly, the association of ecto-
nucleotidase activity and parasite virulence seems not to be
restricted to Leishmania, given that it has been reported also in
Trypanosoma cruzi [88], Toxoplasma gondii [89] and Legionella
pneumophila [90]. These studies suggest that the hydrolysis of
extracellular ATP to adenosine, in addition to fuel the purine
salvage pathway,may also contribute to themodulation of the
host immune response. In fact, we have shown that inhibition
of adenosine receptors during infection by L. braziliensis in-
crease the production of inflammatory cytokines and de-
creases tissue parasitism [84]. The fact that extracellular
adenosine can modulate the immune response against the
parasite suggests a potential role of ectonucleotidases in the
virulence of the parasite. Corroborating this hypothesis, we
and others have shown a correlation between the level of
ectonucleotidase activity and expression and the virulence of
the parasite, for both Leishmania and T. cruzi [86,88,91]
Interestingly, in addition to the production of extracellular
adenosine, it has also been demonstrated that E-NTPDases of
T. cruzi and L. amazonensis are involved in the attachment of
the parasite to the host cell [83,92].
Finally, it has been shown that, although L. amazonensis
triggers the release of neutrophil extracellular traps [10], the
parasite's 30-ectonucleotidase is capable of degrading these
traps [93], enhancing even more the contribution of ectonu-
cleotidases to the control of the innate immune response at
the first moments of interaction between the parasite and the
host cells.
Collectively, these results indicate that, in addition to their
role in the insect saliva, ectonucleotidases from the parasite
are important tools to evade the innate immune response and
should be considered as potential targets for vaccine devel-
opment against Leishmania.Purinergic signaling and immune response
Once inoculated in the dermis of the host Leishmania pro-
mastigotes are phagocytized by cells present at the site of
infection. Although the macrophage is the cell in which the
parasite proliferates and persist to establish the infection, it
has been demonstrated that Leishmania are also phagocytized
by neutrophils and dendritic cells and this interaction can
modulate the immune response to the parasite.
Neutrophils rapidly infiltrate the site of infection and
phagocytize the inoculated promastigotes [8,9]. It has been
proposed that interaction of the parasite with these cells in-
duces neutrophil apoptosis. The interaction of the apoptotic
neutrophil loaded [12] or not [8] with the parasite would then
deactivate the macrophage, favoring parasite survival within
the phagolysosome. As mentioned above, Leishmania also in-
duces the release of NET (neutrophil extracellular traps) by
neutrophils andmay also degrade the nucleic acids present in
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Although no direct proof has been yet provided, it is
conceivable that nucleic acid hydrolysis may release adeno-
sine which, by acting on the adenosine receptors A2A and/or
A2B, could modulate the host immune response.
Dendritic cells have also been shown to be infected by
Leishmania promastigotes [94]. This infection is capable of
modulating the dendritic cell ability to present antigen to T
cells thus affecting the establishment of the adaptative im-
mune response [18,95e98]. Our group has shown that, at least
part of themodulatory effect of the infection on the activation
of dendritic cells (expression of CD40) is dependent on the
activation of the A2B adenosine receptor, mediated by the
production of extracellular adenosine originated by the
increased ectonucleotidase expression (CD39 and CD73) on
the surface of infected cells [18]. In addition, this study also
shows that inhibition of dendritic cell activation interferes
with T cell proliferationwhich can be reverted by the blockade
of the A2B adenosine receptor.
Infection of macrophages by Leishmania is dependent on
the phagocytosis of the parasite. Interestingly, an increased
expression of P2X7 receptors is observed in infected macro-
phages [99,100]. Due to the upregulation of the P2X7 receptors,
addition of extracellular ATP to infected macrophage cultures
reduces the percentage of infected macrophages, suggesting a
possible role of these receptors in the control of the parasite.
The control of parasite growth by activated P2X7 receptors
seems to be mediated by the production of LTB4 [101].
In spite of the expression of P2X7 receptor by infected
macrophages and the ability of added extracellular ATP to
control parasite proliferation, Leishmania survives within
these cells, indicating that other purinergic signaling mecha-
nisms may exist in the infected macrophage. In fact, we have
observed thatmacrophages infected by L. amazonensis express
high levels of CD39 and CD73 and that inhibition of the A2B
adenosine receptor during infection favors the survival of the
parasite (unpublished observations). Furthermore, we have
demonstrated that activation of the adenosine A2B receptor
inhibits the production of NO and IL-12 by infected macro-
phages even in the presence of activating stimuli such as IFN-
gamma and LPS [87], allowing for the enhanced survival of the
parasite. Corroborating these findings, a recent study
demonstrated increased expression of the A2B in monocytes
from patients with visceral leishmaniasis and the possible
involvement of the activation of this receptor with IL-10 pro-
duction by infected cells [102].Conclusion
Several lines of evidence indicate that purinergic signaling
interferes withmany aspects of the immune response against
Leishmania. These findings provide a different approach to
mechanisms of immune response evasion by the parasite
similar to those being investigated in several types of tumors.
Although in its initial phases, the field seems promising and
may contribute to the development of new therapeutic ap-
proaches to the control of parasite progression via the acti-
vation of P2X7 receptors or inhibition of adenosine receptors.Conflict of interest
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